The approach could enable 30-minute testing for a heart condition that is newly treatable following recent drug approvals.

Illumina paired-end reads had an average length of 442 ± 5 base pairs (bp), while PacBio and ONT produced single-end reads with average lengths of 1,453 ± 25 bp and 1,412 ± 69 bp, respectively.

Illumina’s first quarter 2025 results were in line. Revenue and EPS were $1.04 billion and $0.97 (non-GAAP), respectively. No real surprise there. The news was in Illumina’s updated guidance.

Illumina’s stock closed Wednesday at $84.20 per share, down 32 cents. Its stock value is down about 36% year to date, as the company has also been trying to rebound from its failed $7.1 billion ...

Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale ...

Sunningdale Tech, for example, provided critical components for Illumina’s DNA sequencing kits, and tapped other local enterprises for services like the procurement of packaging.

Illumina’s shares have fallen some 26.4% over the past year to US$100.24 as at Feb 14. Nasdaq was shut on Feb 17 for Presidents Day. After notching a 52-week high of US$156.66 in November 2024, ...

What Else: Illumina is anticipated to release 2024 fiscal-year fourth-quarter earnings on Thursday after the market closes. Analysts estimate earnings per share of 92 cents and revenue of $1.08 ...

Illumina (NASDAQ:ILMN) just teamed up with NVIDIA (NASDAQ:NVDA) to shake up the genomics and drug discovery gameand investors, take note. This partnership fuses Illumina's top-notch sequencing ...

In moves that continue to strengthen its affiliation with the healthcare industry, NVIDIA has added three new companies to its growing list of AI-based partnerships. The tech company has partnered ...